CSI Market
Sign In | Register

Briacell Therapeutics (BCTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BCTX quarterly Cash Flow →
The data below summarizes Briacell Therapeutics's cash flow activity from Jul 31 2021 to Jul 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Jul 31 2025)
12 Months 		(Jul 31 2024) (Jul 31 2023) (Jul 31 2022) (Jul 31 2021)
Operating Activities
Income-26.31
Depreciation & amortization0.09
Amortization of Other Assets0.02
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.78
Income (Loss) from Equity Method Investments-0.22
Fair Value Adjustment of Warrants-0.76
Financial Income Expenses Net-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.06
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities-0.73
Increase (Decrease) in Accounts Payable-3.89
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.49
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net-0.24
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-28.17
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds7.32
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.33
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-7.65
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock50.90
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock50.90
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Repayment Government Grant-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities45.45
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-28.17
Total Cash Flow9.63
4 historic quarters locked

Sign in to unlock the full Briacell Therapeutics cash flow history.

Sign In Create Free Account

About Briacell Therapeutics Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20250731)
  • Filed with the SEC: October 15, 2025
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-25-018212

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License